NEW YORK, May 10 – Orchid Biosciences reported revenues of $5.6 million for the first quarter of 2001 Thursday, up from $3.5 million in the comparable quarter last year.

Orchid attributed the revenue increase to sales of its SNPstream SNP scoring and DNA testing services, collaboration and license fees, and revenues from Cellmark Diagnostics, a genetic testing company Orchid acquired in February of 2001.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

In Science this week: in vitro generation of human reproductive cells, and more.